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Abstract
The discovery of rare genetic variants through Next Generation Sequencing
is a very challenging issue in the field of human genetics. We propose a novel
region-based statistical approach based on a Bayes Factor (BF) to assess evi-
dence of association between a set of rare variants (RVs) located on the same
genomic region and a disease outcome in the context of case-control design.
Marginal likelihoods are computed under the null and alternative hypotheses
assuming a binomial distribution for the RV count in the region and a beta or
mixture of Dirac and beta prior distribution for the probability of RV. We de-
rive the theoretical null distribution of the BF under our prior setting and show
that a Bayesian control of the False Discovery Rate (BFDR) can be obtained for
genome-wide inference. Informative priors are introduced using prior evidence
of association from a Kolmogorov-Smirnov test statistic. We use our simula-
tion program, sim1000G, to generate RV data similar to the 1,000 genomes
sequencing project. Our simulation studies showed that the new BF statistic
outperforms standard methods (SKAT, SKAT-O, Burden test) in case-control
studies with moderate sample sizes and is equivalent to them under large sam-
ple size scenarios. Our real data application to a lung cancer case-control study
found enrichment for RVs in known and novel cancer genes. It also suggests
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that using the BF with informative prior improves the overall gene discovery
compared to the BF with non-informative prior.
Bayes Factor; Bayesian FDR; Gene-based analysis; Rare variant; Whole Ex-
ome Sequencing study.
1 Introduction
The emergence of new high-throughput genotyping technologies, such as Next Gener-
ation Sequencing (NGS), allows the study of the human genome at an unprecedented
depth and scale (Lee et al., 2014). They provide invaluable opportunities to deci-
pher the biological processes involved in complex human diseases, such as cancers, in
particular to understand the complex molecular mechanisms leading to cancer devel-
opment and progression (Mardis, 2009). With the advances of NGS technology and
its deep coverage capacity, there have been increased interests in the analysis of rare
single-nucleotide variants (SNVs), e.g., minor allele frequency (MAF) less than 1%,
as reviewed in Gibson (2012). Besides, the genetic variability explained by common
SNPs identified through genome-wide association studies (GWAS) has been generally
low and it is hypothesized that some of the unexplained variability might be due to
rare variants (RVs) (Manolio et al., 2009).
For example, a recent application of NGS to a lung cancer study has led to the
successful identification of 48 germline RVs with deleterious effects on lung cancer
in known candidate genes such as BRCA2 in a sample of 260 case patients with
the disease and 318 controls (Liu et al., 2018). This study underlines the significant
contribution of germline RVs to the genetic susceptibility of lung cancer but it also
raises some concerns. The identification of RVs was based on the application of the
Burden test statistic (Lee et al., 2014), which is powerful only when the RVs have
the same direction of effects in the same gene (e.g. all RVs are deleterious), and
it only focused on candidate genes. The motivation for our paper is to propose a
more general statistical framework able to identify genes across the entire genome
exhibiting RV count differences between cases and controls, where the RVs can be
protective or deleterious within the same gene. It could therefore help disentangle the
contribution of RVs to the genetic susceptibility of lung cancer and of other complex
human diseases.
The discovery of RVs through NGS raises many statistical challenges. Since RVs
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have extremely low frequencies, traditional strategies that analyze one variant at a
time are underpowered for detecting associations with RVs. Gene-level statistics can
provide a first step in the analysis of RVs. Once a gene has been implied as associ-
ated with a disease outcome, based on statistical evidence, a variant-level assessment
could follow that relies on in-depth genetic, experimental and informatic analyses
(MacArthur et al., 2014). Besides, gene-based groupings can lead to biological in-
terpretation and be further validated by functional experiments, including studies on
model organisms and cell lines (Cirulli, 2016; Sung et al., 2014).
The general principle for RV analysis of these methods is usually to collapse in-
formation across multiple RVs from the same gene or genomic region and to test
an association between the cumulative effects of multiple RVs with the response of
interest. These methods can be broadly categorized into five main classes: burden
tests, adaptive burden tests, variance-component tests, combined burden and vari-
ance component tests, and the exponential-combination (EC) test (See Table 2 in Lee
et al. (2014) for a review). Bayesian analysis is not well developed for RV analysis
but has had relevant applications in the context of genetic association studies. For
instance, the Bayes factor (BF) has been attractive because it provides a natural
framework for including prior information (Wakefield, 2009; Spencer et al., 2015). Of
note, two region-based RV tests introduced hierarchical Bayesian models to integrate
some prior information on genetic variants (Yi and Zhi, 2011; He et al., 2015) but
they have not proposed any genome-wide inference control procedure specific to the
BF itself and lack theoretical justifications for region-based inference.
We propose here a novel region-based statistic based on a BF approach to assess
evidence of association between a set of RVs located on same chromosomal region
and a disease outcome in the context of case-control design. Section 2 describes
the data generated by NGS technology. Section 3 defines our model setting, the
BF derivation for gene-based analysis and some asymptotic results about the BF
distribution. Section 4 introduces a Bayesian False Discovery Rate control procedure
for genome-wide inference. Section 5 presents simulation results comparing the BF
to popular competing approaches. Section 6 concludes with a real data application
on a case-control lung cancer study.
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Figure 1: Example of NGS data. The left panel displays the NGS data, presented
by IGV software, a visualization tool for large scale genomic data. The right panel
demonstrates an example region with 10 loci. To detect the genetic association,
we derive the test statistic to compare the RV rate between cases and controls by
assuming that the RV count of each individual x follows Binomial distribution (see
Section 3.1).
2 The NGS Data
The analysis of NGS data involves a number of pre-processing steps. Once the data
have been pre-processed, a sequenced genomic region can be displayed as in Figure
1 (left panel) using for example the sequence viewer software IGV (Robinson et al.,
2011). The top bar represents the sites with genetic variations in a specific region
of the genome. The genotypes of individuals are represented below, where the grey
colour is the reference genotype, dark blue the heterozygote individuals and light
blue the homozygotes for the rare allele, often coded as 0,1 or 2. The analysis of RVs
generally focuses on bi-allelic sites (genetic locus with two possible alleles) with MAF
less than 1%. The genotypes can then be recoded in 0 or 1 since the homozygote
category is less common, where 1 or 0 indicates whether an individual carries the RV
or not. In association studies, the goal is often to compare the distribution of RV
counts in cases and controls (Figure 1, right panel). An example of distribution of RV
proportions for the gene CHEK2 in a sample of 260 cases and 259 controls is given
in Web Appendix A. We observe that cases have a higher density corresponding to
higher proportion of RVs, which could reflect an enrichment of RVs in this gene.
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3 Model
3.1 Model Setting
We propose a region-based statistic by modelling the count of RVs in a specific chro-
mosomal region, e.g. a gene, as shown in Web Appendix A. Let Xijk be the count of
RVs in the region i, for group j and individual k, with i ∈ {1, ...,m}, j ∈ {1, 2} (1
for the control group, 2 for the case group) and k ∈ {1, ..., Nj}. We assume that the
occurrence of a RV at any given site of the region follows an independent Bernoulli
process. The distribution of Xijk is therefore binomial
Xijk ∼ binomial(nijk, pijk)
where pijk is the true, unobserved rate of RV at a single locus of the region and nijk
is total number of sites in the region i for group j and individual k.
We suppose that pijk varies across genetic regions and individuals, according to
a prior density function g(pijk|θij), with θij ≡ θi1 if j is in the control group and
θij ≡ θi2 if j is in the case group. Our goal is to assess whether there is a difference
in RV counts between cases and controls in a particular region i by comparing :
Hi0 : θi1 = θi2 = θi vs. Hi1 : θi1 6= θi2 using the BF statistic.
3.2 BF derivation under case-control design
By definition, the BF is the ratio of the marginal likelihoods of the observed data un-
der H1(m1(X)) and H0(m0(X)). We derive the BF assuming a case-control sampling
design.
Let X ≡ XN = (X1, ..., XN) be the vector of RV counts and P ≡ PN =
(p1, ..., pN) the vector of RV proportions over N(= N1 + N2) individuals. Under
H0, the marginal likelihood is
m0(X) =
∫
P
f(X|P )g(P )dP ,
=
∫
P
f(X|P )
∫
θ
g(P |θ)pi(θ)dθdP .
(1)
where f denotes the binomial distribution probability mass function, g the prior
density function for P , and pi the density function for the parameter θ that we are
interested to compare between cases and controls.
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Under H1, the marginal likelihood is written as a product of two marginal likeli-
hood functions over cases and controls
m1(X) =
∫
P1
f(X1|P1)g(P1)dP1
∫
P2
f(X2|P2)g(P2)dP2,
=
∫
P1
f(X1|P1)
∫
θ1
g(P1|θ1)pi(θ1)dθ1dP1
∫
P2
f(X2|P2)
∫
θ2
g(P2|θ2)pi(θ2)dθ2dP2.
(2)
where X1 and P1 are the vector of RV counts and rates in controls and X2, P2 in
cases. Thus, we have X ≡ (X1,X2) and P ≡ (P1,P2). The marginal likelihoods are
calculated using the Laplace approximation.
3.3 Prior specification
Since the proportions of RVs across individuals can be anywhere between 0 and
1, we assume that these proportions for each genomic region within each group of
individuals follow a beta distribution or a mixture of Dirac and beta distribution.
The mixture prior distribution is proposed to capture the excess of zero counts in the
distribution of RV counts as illustrated in Web Appendix A. The beta distribution
has long been a natural choice to model binomial proportions as it is a conjugate
prior distribution of the binomial distribution with a support interval of [0, 1].
For the beta prior, we assume
pijk|θij ∼ beta(ηij, Kij), with θij ≡ (ηij, Kij).
Here the beta distribution is parametrized in terms of mean (denoted by ηij) and
precision (denoted by Kij). Compared with the traditional parameterization of the
beta(α, β) distribution, the parameters have the following relationship:
η =
α
(α + β)
, K = α + β.
With the beta prior, the marginal distribution of RV count in the region is beta-
binomial. It assumes a similar pairwise correlation between the RV within the region
measured by the intraclass correlation ρ = 1/(1 + K). Our simulation studies and
real data analysis showed that the beta-binomial distribution provided a very good
fit of the RV rate (Web Appendix B) as well as the pairwise correlation coefficient
between RVs (Web Appendix C) within a gene.
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For the mixture prior, we assume that pijk follows a mixture distribution of a point
mass at zero and a beta distribution with parameters ηij and Kij, with probability
w0ij and w1ij = 1− w0ij, respectively. The distribution of Xijk becomes
Xijk =
{
0, if pijk = 0 with P (pijk = 0) = w0ij,
Xijk ∼ Bin(nijk, pijk), if pijk > 0 with P (pijk > 0) = 1− w0ij.
Also when pijk > 0, the prior density for pijk is beta(ηij, Kij).
For both the beta prior and mixture prior, we assume (ηij, Kij) ≡ θi1 ≡ (ηi1, Ki1)
if j is in the control group or (ηij, Kij) ≡ θi2 ≡ (ηi2, Ki2) if j is in the case group. In
addition, for the mixture prior, we also have w0ij ≡ w0i1 or w0ij ≡ w0i2 if j is in the
control or case group, respectively. Our BF statistic aims to compare ηi1 and ηi2 or
both (ηi1, w0i1) and ( ηi2, w0i2). We further assumed the same Kij ≡ Ki in cases and
controls, which fitted well our data, according to the marginal likelihood criteria.
The precision parameterKi captures the variation of the proportion of RVs relative
to the group mean. Under both beta and mixture prior, Ki can be estimated for each
region using the MLE.
3.4 BF Calculation
The BF is calculated for each genomic region (or gene) i. For the sake of presentation,
we omit the index i in this section.
3.4.1 BF with beta prior
To compare the distribution of RVs in cases and controls, our hyperparameters of
interest are η, η1 and η2. The null and alternative hypotheses can be formulated as
H0 : η1 = η2 = η
H1 : η1 6= η2
We assume a hyper prior structure where each hyperparameter is assumed to follow
a beta distribution with new mean parameters (η∗, η∗1, η
∗
2 for η, η1, η2, respectively)
and new precision parameters (K∗, K∗1 , K
∗
2 for η, η1, η2, respectively).
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The marginal likelihood of the data X under H0 is
m0(X|K, η∗, K∗) =
∫
η
∫
P
f(X|P)g(P|η,K)dP pi(η|η∗, K∗)dη,
=
2∏
j=1
Nj∏
k=1
(
njk
xjk
)∫
η
∏2
j=1
∏Nj
k=1 B{xjk +Kη, njk − xjk +K(1− η)}
B{Kη,K(1− η)}N∫
P
2∏
j=1
Nj∏
k=1
p
xjk+Kη−1
jk (1− pjk)njk−xjk+K(1−η)−1
B{xjk +Kη, njk − xjk +K(1− η)}dP
ηK
∗η∗−1(1− η)K∗(1−η∗)−1
B(K∗η∗, K∗(1− η∗)) dη,
=
2∏
j=1
Nj∏
k=1
(
njk
xjk
)∫ 1
0
∏2
j=1
∏Nj
k=1B{xjk +Kη, njk − xjk +K(1− η)}
B{Kη,K(1− η)}N
ηK
∗η∗−1(1− η)K∗(1−η∗)−1
B{K∗η∗, K∗(1− η∗)} dη.
(3)
The marginal likelihood of the data X under H1 is
m1(X|K, η∗1, K∗1 , η∗2, K∗2) =
2∏
j=1
Nj∏
k=1
(
njk
xjk
)
×
2∏
j=1
∫ 1
0
∏Nj
k=1B{xjk +Kη, njk − xjk +K(1− η)}
B{Kη,K(1− η)}Nj
ηK
∗
j η
∗
j−1(1− η)K∗j (1−η∗j )−1
B{K∗j η∗j , K∗j (1− η∗j )}
dη.
(4)
The BF is the ratio of marginal likelihood underH1 and underH0: BF =
m1(X|K,η∗1 ,K∗1 ,η∗2 ,K∗2 )
m0(X|K,η∗,K∗) .
In this expression, we consider a fixed K and estimate its MLE, K˜, from the whole
sample under the null hypothesis. Therefore,
BF =
m1(X|K˜, η∗1, K∗1 , η∗2, K∗2)
m0(X|K˜, η∗, K∗)
. (5)
The integral part in the above BF formula is calculated using Laplace approxima-
tion (see equations (1) and (2) of Web Appendix D). The accuracy of this approxi-
mation is evaluated in Web Appendix E.
3.4.2 hyperparameter specification
We use empirical Bayes estimates for the parameters η∗, η∗1 and η
∗
2 in the hyperprior
distribution, i.e., η∗ = ηˆ, η∗1 = ηˆ1, η
∗
2 = ηˆ2, where ηˆ is the MLE of the param-
eter η in the likelihood function f(X|η, K˜) =
∫
P
f(X|P)g(P|η, K˜)dP obtained by
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ηˆ = argmax
η
log f(X|η, K˜). The estimates of η1 and η2 are obtained in a similar way
by the MLE computed separately in controls and cases but assuming the same K˜,
i.e. ηˆ1 = argmax
η
log f(X1|η, K˜) and ηˆ2 = argmax
η
log f(X2|η, K˜). The other hyper-
parameters K∗1 , K
∗
2 and K
∗ are interpreted as precision parameters of the mean RV
counts in controls, cases and whole sample, respectively. Our rationale for defining
these hyperparameters is to get convenient asymptotic results for the BF distribution
and to be able to introduce informative prior at the region level. Therefore, we set
K∗ = p2ηˆΣˆ−1, K∗1 = ηˆ1Σˆ
−1
1 and K
∗
2 = ηˆ2Σˆ
−1
2 , where Σˆ, Σˆ1 and Σˆ2 are the estimated
variances of ηˆ, ηˆ1 and ηˆ2, respectively. In the expression of K
∗, p is a term that
allows to introduce informative prior at the region (or gene) level. The role of p is
to influence the precision parameter K* under the null hypothesis (denominator of
equation (5)), where p < 1 leads to a smaller K* in equation (5) and thus more uncer-
tainty on the prior of . This yields less evidence for the null hypothesis in comparison
with the situation p = 1 and thus stronger evidence for association. Because the ef-
fect of this prior is to force the evidence towards association (alternative hypothesis)
when p → 0, we refer to this prior as ”informative” and the situation where p=1 as
”non-informative”, since in this latter case, no attempt to influence either hypothesis
is made. Indeed, in section 3.5 below, we explain that p can be obtained from the
p-value of a Kolmogorov Smirnov (KS) test, comparing the distribution of RV counts
within the region of interest between cases and controls. We can prove that under
H0, when p = 1, 2 logBF
d−→ χ2(1). When p < 1 and assuming independence be-
tween the BF with non-informative prior and the KS component, we show that with
our definition of K∗ above (in particular the use of p2 in this expression), we obtain
2 logBF
d−→ χ2(3) (see section 3.6 and Web Appendix D). Thus, more information is
added to the BF and it will give more evidence for association when it can overcome
the additional 2 degrees of freedom provided by the KS test p-value.
3.4.3 BF with mixture prior
We now assume that the RV counts among individuals are ordered with x(1) =
x(2) = ... = x(M) = 0 and x(M+1), ..., x(N) > 0. Let 0 < M < N and the variance
V ar(x(M+1), ..., x(N)) > 0, for the mixture prior to be defined. As noted previously,
the prior distribution for pjk can be written as
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g(pjk|w0j, ηj) =
w0j, if pjk = 0,(1− w0j)g(pjk|ηj, K) = (1− w0j)pηjK−1jk (1−pjk)K(1−ηj)−1B(ηjK,K(1−ηj)) , if pjk > 0.
Under the mixture prior, the hyperparameters of interest are w0, w01, w02, η, η1,
and η2. Similar to 3.4.1, we assume a hyper prior structure where each hyperparameter
is assumed to follow a beta distribution
η ∼ beta(η∗, K∗), η1 ∼ beta(η∗1, K∗1), and η2 ∼ beta(η∗2, K∗2),
w0 ∼ beta(η∗∗, K∗∗), w01 ∼ beta(η∗∗1 , K∗∗1 ), and w02 ∼ beta(η∗∗2 , K∗∗2 ).
We propose to perform two comparisons, first compare η1 and η2 with fixed w0j
and second, compare both (η1, w01) to (η2, w02). The derivation of this BF follows
the same principle as the BF with beta prior shown before and the details are given
in Web Appendix F.
3.5 Informative prior
As explained in section 3.4.2, we choose p as the probability of association from a
Kolmogorov Smirnov (KS) test derived as follows. First, we conduct a single RV test
between cases and controls for all variants in region i as explained below; Second,
we compare the set of region-specific p-values to a null p-value distribution using
a one-sided one-sample KS test (ie. we expect a higher proportion of low p-values
for associated genes). The null distribution is empirically estimated using all the
genes simulated under H0 in the simulation study or all the genes across the genome
in the real data analysis. The advantage of this prior is that it can capture RV
allelic differences between cases and controls through the KS test and those RVs
can have opposite effects within the same gene. The other advantage is that it is
almost uncorrelated with the BF assuming non-informative prior and thus provides
convenient asymptotic results for the BF with informative prior. The rationale is that
the BF with non-informative prior compares the overall RV count between cases and
controls but does not depend on the differences in RV allelic frequencies at individual
sites between them, while the KS component is based on allelic distribution differences
between cases and controls at individual sites within the region. Evidence for the very
low correlation is given in Web Appendix G.
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For the single RV test, for each single variant v in region i, let Yi1v and Yi2v
be the RV counts within cases and controls. We transform the observed RV count
Yijv to obtain the count Y˜ijv = Yijv ∗ Cv, where Cv is the largest integer ≤ 0.01Pv
and Pv is the MAF of variant v. In this way, all the single RV p-values can be
comparable regardless of their MAF. We assume Y˜ijv has a Poisson distribution with
Y˜i1v ∼ Poisson(λ1vN1) and Y˜i2v ∼ Poisson(λ2vN2). The parameters λ1v and λ2v
correspond to the probabilities of a control or a case to have a RV at site v. Our
interest is to test λ1v = λ2v. When both λ1vN1 and λ2vN2 are large, the normal
distribution is a good approximation of the Poisson distribution. Define r = N2
N1
and
Wiv = rY˜i1v − Y˜i2v, under H0, we have
Wiv − E(Wiv)√
V ar(Wiv)
≈ rY˜i1v − Y˜i2v√
r2Y˜i1v + Y˜i2v
∼ N(0, 1). (6)
Since λ1v and λ2v are usually small, the condition that both λ1N1 and λ2N2
are large is met only when the sample sizes N1 and N2 are large. Besides, for the
validity of these variant level comparison tests, we recommend excluding the sites
with y˜1k + y˜2k < 5 and those with extremely low MAF, e.g. MAF < 0.1%. We
conduct two-sided test against H0: λ1v = λ2v for each RV.
3.6 Asymptotic property of the BF statistic under the null
hypothesis
For region-based inference (i.e. testing one region at the time) or genome-wide infer-
ence (testing all regions simultaneously), it is critical to know the asymptotic distri-
bution of the BF under the null. Given a known null distribution of BF, the p-value
corresponding to each region-based BF can be derived. The problem of genome-wide
inference is addressed in the next section.
In this section, η0 denotes the true value of η. Based on the likelihood func-
tions Pr(X|η), Pr(X1|η1) and Pr(X2|η2), by definition of the MLE, we have under
H0, ηˆ ∼ N(η0,Σ), ηˆ1 ∼ N(η0,Σ1), and ηˆ2 ∼ N(η0,Σ2). In addition, we define
Σ−1 ≡ −d2 logPr(X|η)
dη2
|η=η0 , Σ−11 ≡ −d
2 logPr(X1|η)
dη2
|η=η0 and Σ−12 ≡ −d
2 logPr(X2|η)
dη2
|η=η0 .
The asymptotic distribution depends on the prior specification. Under a particular
prior specification, we show the following result:
Proposition 1: Under H0, ηˆ ≈ ηˆ1Σ2+ηˆ2Σ1Σ1+Σ2 and Σ = Σ1Σ2Σ1+Σ2 . (See Web Appendix H for
a proof).
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Theorem 1: For the BF with beta prior, assuming that the parameters in the hyper-
prior distribution are defined by η∗ = ηˆ, η∗1 = ηˆ1, η
∗
2 = ηˆ2, K
∗ = p2ηˆΣˆ−1, K∗1 = ηˆ1Σˆ
−1
1
and K∗2 = ηˆ2Σˆ
−1
2 , where p is a random variable with uniform distribution in (0,1).
When K∗η∗ →∞, K∗1η∗1 →∞ and K∗2η∗2 →∞, sample size of cases N1 →∞ and of
controls N2 →∞, and also η0 → 0, we have 2 logBF d−→ χ2(3) , under H0. Assuming
p = 1 leads to non-informative priors with 2 logBF
d−→ χ2(1). The full proof of the
Theorem 1 is given in the Web Appendix D.
When using the BF with informative prior (p 6= 1), p in the Theorem 1 corresponds
to the p value of the KS test (see section 3.5), assumed uniform distributed under
the null hypothesis. We also assumed the independence between the BF with non-
informative prior and the KS test component (−2 log p). Although a formal proof is
not available, we showed in the simulated data and real data application that these
two components are almost uncorrelated (Web Appendix G).
The derivation of the asymptotic results under H0 for the BF with mixture prior
follows the same principles as for the BF with beta prior (see Web Appendix F).
4 Bayesian False Discovery Rate (FDR) for genome
wide inference
The goal of genome-wide inference is to perform a simultaneous testing of multiple
hypotheses (i.e. all the genes or all the genomic regions across the genome). Following
(Wen, 2017), we propose to use the Bayes factor as the test statistic in the Bayesian
decision rule to reject the null hypothesis.
Suppose, we want to test m null hypotheses H0i, i = 1, · · · ,m, using data denoted
as Y . Let Zi = 1 if H0i is false and Zi = 0 if H0i is true, i = 1, · · · ,m. If we denote
pi0 the proportion of data generated under the null hypothesis, we assume that Zi is
unobserved indicator with Zi|pi0 ∼ Bernoulli(1− pi0).
Let δi denote a decision rule in (0, 1) on Zi based on all the observed data and
D =
∑m
i=1 δi. Following (Muller et al., 2006), the False Discovery Proportion (FDP)
is defined as
FDP ≡
∑m
i=1 δi(1− Zi)
max(1, D)
,
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and the Bayesian FDR as:
FDR ≡ E(FDP |Y ) =
∑m
i=1 δi(1− vi)
max(1, D)
,
where vi ≡ Pr(Zi = 1|Y ) is the posterior probability that the observed data is
generated from Hi1 for each test i. The interest in the Bayesian control of the FDR
is vi,
vi =
∫
Pr(Zi = 1|Y, pi0)p(pi0|Y )dpi0 (7)
where
Pr(Zi = 1|Y, pi0) = (1− pi0)BFi
pi0 + (1− pi0)BFi (8)
where BFi is the BF for ith gene, based on either the beta or mixture prior.
The Bayesian control of FDR is then based on the decision rule:
δi(t) = I(vi > t)
It indicates that Hi0 is rejected if the posterior probability that the observed data is
generated from Hi1 is high. For a pre-defined FDR level α0, the threshold tα0 that
controls the FDR at the level α0 is determined by
tα0 = argmin
t
{∑m
i=1 δi(t)(1− vi)
max(1, D(t))
≤ α0
}
(9)
As stated above, the BFDR procedure requires an estimate of vi, which in turn
depends on pi0, the proportion of true null hypotheses (i.e, the proportion of true
non associated genes/regions). The two main approaches to estimate vi are based on
either setting a prior distribution for pi0 (Scott and Berger, 2006) or estimating pi0
from the empirical distribution of the test statistic (Wen, 2017; Storey et al., 2004;
Efron, 2010), i.e. the BF in our situation. To have a general BFDR control procedure,
applicable to both the BF with and without informative prior, we propose to combine
these two approaches to estimate vi in a two-step procedure. The performance of
the two-step BFDR procedure in the context of genome-wide inference is assessed
by simulation studies and compared to competing methods with frequentist FDR
approach. A detailed description of this new BFDR approach and the simulation
results are given in the Web Appendix I.
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5 Simulation study
Principle. We simulated RVs using the R package sim1000G (Dimitromanolakis
et al., 2019), which has the advantage of mimicking MAF distributions and short and
long-range linkage disequilibirum (LD) across RVs similar to the 1,000 genomes data.
We simulated one single region with total number of RV 22, 45, 72 and 145. The
MAF of the RVs was in the range [10−6, 0.01]. The binary phenotype (case-control
status) was generated from a logistic regression where we assumed that 1/2, 1/3, 1/4
and 1/5 of RVs are causal and randomly selected. The effect size for each causal
variant is inversely proportional to its MAF (Wu et al., 2011) and is in the range
[2.23, 4.25]. For each combination of gene size and number of causal variants, we
assumed that 100%, 90% and 75% of the causal variants are deleterious (ie. increase
disease risk) and that the rest are protective. We used sample sizes of 250, 500 and
1000, respectively, for each group of cases and controls, and generated 1000 replicates
of simulated data for each scenario.
Simulations under the null hypothesis. To check the asymptotic null distribution
of the BF with informative prior, we compared the simulated BF distribution to a
χ2(3) distribution using QQ-plots (See Web Appendix J) under various scenarios.
Under most scenarios, the BF using both beta and mixture priors fits well a χ2(3)
distribution under the null hypothesis, except that conservative results (i.e., empirical
type I error lower than nominal type I error) are shown when sample size is equal to
500 or 1000 and number of sites of the gene is equal to 45. In fact, this conservative
result is what we expect when using KS test p-values as informative prior. That is
because when the number of valid p-values calculated within each gene used for KS
test is less than or equal to 30, exact p-value is computed. Otherwise, asymptotic
distributions are used and the resulting p-values are known to be conservative when
sample size (the number of p-values within the gene for the KS test) is small (Conover,
1972).
Methods comparison. We compared the statistical power of BF to three standard
region-based statistical approaches, Burden test, SKAT and SKAT-O (Lee et al.,
2014). The power is estimated using the proportion of replicates with p value less
than 0.05, assuming α = 0.05 for all methods. The Burden test summarizes the
genotype information of multiple RVs in the region into a single genetic score and
test for association between this score and a phenotype. Burden tests assume all the
variants within a region have a same direction of effect on the disease outcome and
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the test statistic can be written as the square of the weighted sum of single-variant
score statistics Q =
(∑n
j=1 wjSj
)2
, where Sj is score statistic of marginal model for
variant j and wj is the weight. The sequence kernel association test (SKAT) is based
on a variance component test within a random-effect model. SKAT can overcome
the limitation of burden test, assuming the multiple variants in one region can have
opposite directions of effect. The SKAT test statistic is a weighted sum of squares
of single-variant score statistics Q =
∑n
j=1w
2
jS
2
j . Since in real data the true genetic
model is unknown, SKAT-O uses the data to adaptively weight the SKAT and Burden
test statistics Q = (1− ρ)Qskat + ρQburden. The parameter ρ in the SKAT-O statistic
is estimated based on a minimum p−value criteria, calculated over a grid of ρ’s.
Type I error results. The simulation results confirmed that the BF null distribution
does not depend on the sample size and gene size. We also assessed the empirical
type I error at nominal level α = 0.05 (Table 1 and Web Appendices K). The type
I error rate is under control under most scenarios, we only noted a slight inflation
of the type I error for the BF with informative prior, when sample sizes ≥ 1000 and
gene sizes = 145. The slight inflation was also confirmed for extremely large genes
(i.e. with 5000 sites) (Web Appendix L).
Power results. Simulation results under the alternative hypothesis are given in
Table 2 (see also Web Appendix K). The BF with informative prior is always more
powerful than using non-informative prior. The power of BF with beta prior is usually
slightly higher than the BF with mixture prior. The BF with informative prior under
beta or mixture prior outperforms all three competing methods under all scenarios for
small sample size (N=500). For medium and large sample sizes (N=1000, N=2000),
under most of situations, SKAT-O performed the best. However, BF with informa-
tive prior sometimes can beat SKAT-O, both of which have very close power when
all causal variants have same direction of effect or when the proportion of opposite
direction variants is low (10%).
BFDR results. We evaluated the BFDR control procedure in the context of
genome-wide inference and compared it to three competing methods (SKAT, SKAT-
O and the Burden test) where Benjamini-Hochberg (BH) FDR procedure (Benjamini
and Hochberg, 1995) was used for multiple test comparisons. The principle of these
simulations are described in Web Appendix M. The BFDR procedure controls well
the FDR nominal level of 0.05 under all scenarios as the other methods do (Web
Appendix Figure 20) except the burden test, which fails when the sample size is
15
Table 1: Type I error rate for the informative prior BF and other competing methods,
at α = 0.05 level, for different gene sizes and sample sizes with 1000 replicates
sites=22 sites=45 sites=72 sites = 145
250 cases, 250 controls
BF (beta informative prior) 5.85% 2.45% 3.51% 4.47%
BF (mixture informative prior) 5.35% 2.45% 3.40% 5.43%
BF (beta non-informative prior) 5.43% 4.04% 3.30% 5.85%
BF (mixture non-informative prior) 4.18% 2.98% 4.89% 5.74%
SKAT 5.53% 3.09% 5.43% 3.09%
Burden 5.21% 3.94% 4.26% 4.89%
SKAT-O 6.60% 3.40% 5.11% 3.62%
500 cases, 500 controls
BF (beta informative prior) 6.91% 4.04% 5.00% 6.49%
BF (mixture informative prior) 6.06% 4.04% 5.96% 7.23%
BF (beta non-informative prior) 4.89% 4.89% 4.04% 4.57%
BF (mixture non-informative prior) 3.72% 4.15% 4.68% 5.85%
SKAT 7.55% 2.13% 5.43% 4.15%
Burden 4.89% 5.21% 3.94% 3.94%
SKAT-O 6.06% 3.94% 4.68% 3.40%
1000 cases, 1000 controls
BF (beta informative prior) 5.53% 5.21% 5.00% 6.06%
BF (mixture informative prior) 4.79% 4.79% 5.32% 7.23%
BF (beta non-informative prior) 4.15% 3.19% 3.62% 4.57%
BF (mixture non-informative prior) 2.66% 2.98% 3.51% 7.23%
SKAT 3.72% 2.87% 3.09% 5.32%
Burden 3.83% 3.51% 3.62% 5.74%
SKAT-O 4.04% 2.87% 2.98% 5.53%
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small (N1=N2=250) and both deleterious and protective variants are present in the
gene (Web Appendix Figure 21). For small sample sizes, N1 = N2 = 250, the BF
with BFDR procedure was superior to all other methods based on true discovery
rate (TDR) values. For intermediate sample sizes, N1 = N2 = 500, the BF with
BFDR procedure was superior to the Burden test and the performances were simi-
lar to SKAT and SKAT-O. For large sample sizes, N1 = N2 = 1000, all methods
achieved similar TDR levels.
6 Application
Design. We apply the BF approach to a whole-exome sequencing (WES) study
on lung cancer, which includes 262 patients affected by lung cancer and 261 healthy
controls all recruited in Toronto. In the original variant call format (VCF) file of the
study, there were totally 2,017,458 sites, including not only DNA polymorphism data
but also rich annotations. We performed quality control procedures before conducting
the BF analysis (See Web Appendix N).
Results. We calculated the BF with non-informative prior assuming either the
beta or mixture prior for 13,738 genes (>=20 sites) and the BF with informative
prior for 11,721 genes, which all contain at least 5 RVs for the KS test after exclud-
ing RVs that have total standardized counts less than 5 and MAF < 0.1%. We
compared the distribution of 2× log(BF ) assuming non-informative and informative
priors, which under the null are χ2(1) and χ2(3), respectively, using QQ plots (See
Figure 2). Despite the increase in degrees of freedom, the distribution of BF with
informative prior deviates more from the null distribution compared with the BF with
non-informative prior and leads to increased gene discovery.
For instance, for the top 20 genes identified by the BF assuming an informative
beta prior, the p-value varies between 4.88 × 10−10 and 8.32 × 10−4 while it ranges
from 5.07 × 10−5 to 0.92 assuming a BF with non-informative beta prior (Table 3).
The difference between these 2 BFs is explained by the contribution of the KS test,
which is significant at the 5% level for 16 of the 20 top genes. Among these 20 genes,
6 of them are also ranked in the top 20 according to the BF with non-informative beta
prior (i.e. REG4, TLR6, ERAP2, PLEKHG7, ANKRD44, and INTS7). Among
the top genes identified by the BF with an informative prior, the two highest BFs
correspond to the genes KCNIP4 (p=4.88 × 10−10 and p=1.55 × 10−7) and GPC5
(p=5.12×10−10 and p=1.55×10−7) assuming either a beta prior (Table 3) or a mixture
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prior (Web Appendix Table 4). The KS test is very significant for these 2 genes
(p=9.54 × 10−11 and p=3.23 × 10−8), which shows the interest of using informative
prior in our BF framework. Besides, 11 out of the top 20 genes identified by the
BF with informative beta prior overlap with those identified by the BF with mixture
informative prior. Among the top 20 genes detected by the BF with informative beta
prior, 12 and 2 overlap with the top 100 genes ranked according to the Burden and
SKAT tests, respectively. Of note, the top 2 genes selected by the BF ranks very low
with the Burden and SKAT tests, i.e. 10745 and 459 for KCNIP4, respectively, and
8601 and 5955 for GPC5. The difference between the informative BF and the Burden
test might be explained by the contribution of the KS component to the BF. Finally,
comparing the top gene list identified by different approaches, we did not notice any
excess of large genes (≥ 100 sites) with the BF with informative prior compared to
the competing methods (Web Appendix Table 6). For SKAT results, we sought to
better understand the difference with the BF below.
Difference between BF and SKAT. The top 20 genes identified by each competing
method are given in Web Appendix Table 5. Four of the top genes identified by
SKAT-O overlap with the BF with informative prior and most of the genes identified
by the Burden test are also ranked among the top with the BF. In Web Appendix
Figure 22, we have presented 2 genes KCNIP4 and Y AP1 that show a large dis-
crepancy in their rank according to the BF and SKAT. The top gene identified by
BF, KCNIP4, exhibits a large difference in individual-RV associated p-values when
compared the the null distribution, especially in the lower tail of the distribution (i.e.
small p-values). This difference is likely to contribute to the significance of the KS
test used as prior in the BF with informative prior. Such difference is not observed
for the gene Y AP1, the top fifth gene identified by SKAT. On the other hand, the
distribution of RV counts between cases and control shows a systematic difference for
the gene Y AP1, with very few zeros, which is likely to contribute to the significance
of the SKAT test.
BFDR evaluation. We also applied the BFDR control procedure using the upper
bound estimates of pi0. Given γ = 0.999, q
∗
γ = 16.27, with the number of genes
(hypotheses) to test using beta and mixture informative prior BF are 11,721 and 9,368
respectively, the corresponding pˆi0 using these two methods are 99.90% and 99.97%.
The BFDR level of gene KCNIP4 and GPC5 are 6.09 × 10−5 and 1.07 × 10−2 with
beta prior and 7.16× 10−4 and 8.84× 10−2 with mixture prior.
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Figure 2: QQ plot of the BF test in the lung cancer WES study. The left panel
shows non-informative prior results on 13,738 genes. The green circles represent the
BF results with beta prior and the orange circles with the mixture prior. The right
panel shows results on 11,721 genes (with at least 5 valid p-values within each gene
for KS test). Similarly, green and orange circles correspond to the beta and mixture
prior results, respectively.
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7 Conclusion
Our BF method with informative priors provides a sensitive approach to detect RV
associations with complex diseases based on NGS technology. It has greater power
than competing approaches such as SKAT-O and Burden Test in designs with mod-
erate sample sizes (number of cases and number of controls each < 500), which is
an important result since many NGS applications face this situation including our
real data application. The BF provided better power performances when genes had
a higher proportion of RVs with the same direction of effects (ratio of protective RVs
≤ 10%) in contrast to SKAT-O, which performed better when genes had a higher
proportion of RVs with opposite direction of effects (ratio of protective RVs ≥ 25%).
The problem of protective variants might be less critical in WES where variants are
located within protein-coding genes and have predominantly deleterious effects on the
disease of interest.
Another advantage of our BF approach is the incorporation of informative priors
in the form of a prior probability of association given by a KS test. The BF can then
be thought of as a composite test where the first component is a ratio of marginal
likelihoods comparing the distribution of RV counts among cases vs. controls for a
particular gene using the beta-binomial distribution and the second (independent)
component, the KS test, compares the p-value distribution across RVs in that gene to
an empirical null distribution. It is therefore sensitive to either overall RV counts dif-
ference between cases and controls or allelic distribution differences (or both). Com-
bining different gene-based RV tests has also been found to be an efficient strategy
to detect associations in the recent literature (Lee et al., 2012; Porsch et al., 2018).
An empirical Bayesian approach for genetic associations based on the beta-binomial
distribution has also been proposed by McCallum and Ionita-Laza (2015). In the
framework, the hyperprior parameter of the beta distribution corresponds to the
mean RV probability across individuals unlike our approach which uses the mean
RV probability across a genomic region. A great advantage of our approach over
this paper is that the asymptotic distribution of the BF under the null hypothesis
of no association is provided and a Bayesian FDR procedure is also proposed for
genome-wide inference.
Our real data application illustrates the interest of our approach. Using the BF
with informative prior improves the overall gene discovery compared to the BF with
non-informative prior. Several important genes have been identified by the BF ap-
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proach including the 2 top genes KCNIP4 and GPC5 and 4 known cancer genes.
Interestingly, the gene KCNIP4 has been previously associated with lung cancer in
a large fine-mapping study using common genetic variants and a Bayesian prioriti-
zation approach (Brenner et al., 2015). This gene encodes a member of the family
of voltage-gated potassium (Kv) channel-interacting proteins (KCNIP s), which are
small calcium binding proteins. This gene is believed to play a role in regulation
of Wnt/β-catenin signaling and target gene transcription pathway (Pruunsild and
Timmusk, 2005). The gene GPC5, the glypican Proteoglycan 5, is a member of the
glypican-related integral membrane proteoglycan family (GRIPS) proteins. It has
recently been shown that GPC5 is a novel epigenetically silenced tumor suppressor,
which inhibits tumor growth by suppressing Wnt/β-catenin signaling in lung adeno-
carcinoma (Yuan et al., 2016).
Finally, we only have considered relatively equal sample sizes in our simulations
and application but our method is also applicable to unbalanced case-control designs.
Our framework could also be extended to include covariates, either individual-level
or variant-level covariates. We have not addressed specifically the problem of popu-
lation structure in this paper, which arises when cases and controls are sampled at
differential rates from genetically divergent populations (Devlin and Roeder, 1999).
In our real data analysis, we did not notice any inflation of the BF due to popula-
tion stratification, probably because we used a relatively homogenous population of
European descent.
Acknowledgements
The authors also thank Drs Rayjean Hung and Geoffrey Liu for providing the Lung
Cancer whole-exome sequencing data, Apostolos Dimitromanolakis for creating R
packages sim1000G and rareBF, professors He´le`ne Massam and Michael Escobar for
constructive discussions about the method development.
References
Benjamini, Y. and Hochberg, Y. (1995). Controlling the false discovery rate: A
practical and powerful approach to multiple testing. Journal of the Royal Statistical
Society, Series B 85, 289–300.
Brenner, D. R., Amos, C. I., Brhane, Y., and et al. (2015). Identification of lung can-
22
cer histology-specific variants applying bayesian framework variant prioritization
approaches within the tricl and ilcco consortia. Carcinogenesis 36, 1314–26.
Cirulli, E. T. (2016). The increasing importance of gene-based analyses. Plos Genetics
.
Conover, W. J. (1972). A kolmogorov goodness-of-fit test for discontinuous distribu-
tions. Journal of American Statistical Association 67, 591–596.
Devlin, B. and Roeder, K. (1999). Genomic control for association studies. Biometrics
55, 997–1004.
Dimitromanolakis, A., Xu, J., Krol, A., and Briollais, L. (2019). sim1000g: a user-
friendly genetic variant simulator in r for unrelated individuals and family-based
designs. BMC Bioinformatics 20, 26.
Efron, B. (2010). Large-Scale Inference. Cambridge.
Gibson, G. (2012). Rare and common variants: twenty arguments. Nature Reviews
Genetics 13, 135–145.
He, L., Pitkaniemi, J., Sarin, A. P., Salomaa, V., Sillanpaa, M. J., and Ripatti, S.
(2015). Hierarchical bayesian model for rare variant association analysis integrating
genotype uncertainty in human sequence data. Genetic Epidemiology 29(2), 89–
100.
Lee, S., Abecasis, G. R., Boehnke, M., and Lin, X. (2014). Rare-variant association
analysis: study designs and statistical tests. American Journal of Human Genetics
95, 5–23.
Lee, S., Wu, M., and Lin, X. (2012). Optimal tests for rare variant effects in sequencing
association studies. Biostatistics 13, 762–775.
Liu, Y., Lusk, C. M., Cho, M. H., Silverman, E. K., Qiao, D., Zhang, R., and et al.
(2018). Rare variants in known susceptibility loci and their contribution to risk of
lung cancer. Journal of Thoracic Oncology 13, 1483–1495.
MacArthur, D. G., Manolio, T. A., and Rehm, H. L. e. a. (2014). Guidlines for
investigation causality of sequence variants in human disease. Nature 508, 469–
476.
23
Manolio, T., Collins, F., Cox, N., Goldstein, D., and Hindorff, L. e. a. (2009). Finding
the missing heritability of complex diseases. Nature 461, 747–753.
Mardis, E. (2009). Cancer genome sequencing: a review. Human Molecular Genetics
18, R163–R168.
McCallum, K. J. and Ionita-Laza, I. (2015). Empirical bayes scan statistics for detect-
ing clusters of disease risk variants in genetic studies. Biometrics 71, 1111–1120.
Muller, P., Parmigiani, G., and Rice, K. (2006). Fdr and bayesian multiple compar-
isons rules. ISBA 8th World Meeting on Bayesian Statistics .
Porsch, R. M., Mak, T., Tang, C., and Sham, P. C. (2018). Ks-burden: Assessing
distributional differences of rare variants in dichotomous traits. bioRxiv .
Pruunsild, P. and Timmusk, T. (2005). Structure, alternative splicing, and expression
of the human and mouse kcnip gene family. Genomics 86, 581–593.
Robinson, J. T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E. S.,
Getz, G., and Mesirov, J. P. (2011). Integrative genomics viewer. Nature Biotech-
nology 29, 24–26.
Scott, J. G. and Berger, J. O. (2006). An exploration of aspects of bayesian multiple
testing. Journal of Statistical Planning and Inference 136, 2144–2162.
Spencer, A. V., Cox, A., Lin, W. Y., Easton, D. F., Michailidou, K., and Walters,
K. (2015). Novel bayes factors that capture expert uncertainty in prior density
specification in genetic association studies. Genetic Epidemiology 39, 239–248.
Storey, J. D., Taylor, J. E., and Siegmund, D. (2004). Strong control, conservative
point estimation and simultaneous conservative consistency of false discovery rates:
a unified approach. Journal of the Royal Statistical Society, Series B 66, 187–205.
Sung, Y. J., Korthauer, K. D., Swartz, M. D., and Engelman, C. D. (2014). Meth-
ods for collapsing multiple rare variants in whole-genome sequence data. Genetic
Epidemiology 38, S13–S20.
Wakefield, J. (2009). Bayes factors for genome-wide association studies: Comparison
with p-values. Genetic Epidemiology 33, 79–86.
24
Wen, X. (2017). Robust bayesian fdr control using bayes factors, with application to
multi-tissue eqtl discovery. Statistics in Biosciences .
Wu, M. C., Lee, S., Cai, T., Li, Y., Boehnke, M., and Lin, X. (2011). Rare-variant
association testing for sequencing data with the sequence kernel association test.
American Journal of Human Genetics 89, 82–93.
Yi, N. and Zhi, D. (2011). Bayesian analysis of rare variants in genetic association
studies. Genetic Epidemiology 35(1), 57–69.
Yuan, S., Yu, Z., and et al. (2016). A novel epigenetically silenced tumor suppressor,
inhibits tumor growth by suppressing wnt/-catenin signaling in lung adenocarci-
noma. Oncogene 35, 6120–6131.
25
T
ab
le
3:
T
op
20
ge
n
es
id
en
ti
fi
ed
b
y
th
e
B
F
w
it
h
b
et
a
in
fo
rm
at
iv
e
p
ri
or
C
h
ro
m
os
om
e
G
en
es
#
of
si
te
s
K
S
te
st
1
B
F
(i
n
fo
)2
S
K
A
T
3
B
u
rd
en
4
S
K
A
T
-O
5
B
F
(n
on
in
fo
)
6
in
th
e
ge
n
e
p
-v
al
u
e
p
-v
al
u
e
ra
n
k
ra
n
k
ra
n
k
ra
n
k
4
K
C
N
IP
4
15
90
4
9.
54
E
-1
1
4.
88
E
-1
0
45
9
10
74
5
79
6
93
05
13
G
P
C
5
17
06
7
3.
23
E
-0
8
1.
55
E
-0
7
59
55
86
01
88
13
12
21
0
17
R
A
B
40
B
39
2.
40
E
-0
5
2.
27
E
-0
5
81
4
13
51
11
33
12
86
16
P
A
Q
R
4
37
4.
43
E
-0
4
7.
58
E
-0
5
29
2
26
2
26
5
19
3
12
P
L
E
K
H
G
7
51
1.
97
E
-0
2
7.
62
E
-0
5
23
3
10
2
4
1
R
E
G
4
41
1.
06
E
-0
1
1.
10
E
-0
4
15
40
14
1
4
T
L
R
6
30
1.
76
E
-0
1
1.
83
E
-0
4
16
07
5
10
2
3
E
R
C
2
78
6.
60
E
-0
3
3.
44
E
-0
4
85
2
82
14
4
68
10
Z
F
Y
V
E
27
61
1.
91
E
-0
2
4.
46
E
-0
4
18
07
90
22
4
34
8
O
T
U
D
6B
20
1.
24
E
-0
2
5.
24
E
-0
4
57
72
57
63
17
A
T
P
6V
0A
1
75
5.
07
E
-0
3
5.
25
E
-0
4
10
94
71
15
0
12
5
2
A
N
K
R
D
44
11
0
8.
96
E
-0
2
5.
70
E
-0
4
85
11
57
13
5
7
19
Z
N
F
55
6
42
2.
58
E
-0
2
6.
63
E
-0
4
85
3
38
68
41
10
S
L
F
2
56
2.
58
E
-0
2
7.
22
E
-0
4
77
8
47
78
45
1
IN
T
S
7
66
4.
89
E
-0
2
7.
38
E
-0
4
79
5
34
54
19
16
S
D
R
42
E
1
26
4.
62
E
-0
3
7.
80
E
-0
4
31
1
19
0
25
3
21
6
16
IL
17
C
38
1.
45
E
-0
3
8.
16
E
-0
4
29
23
81
1
17
56
87
0
5
E
R
A
P
2
79
7.
85
E
-0
1
8.
24
E
-0
4
30
96
1
3
3
17
T
R
IM
47
33
3.
23
E
-0
3
8.
29
E
-0
4
15
60
61
3
11
51
33
6
17
B
R
C
A
1
10
2
5.
07
E
-0
3
8.
32
E
-0
4
33
05
56
3
13
41
20
7
1
.
K
S
p
-v
a
lu
e
u
se
d
a
s
th
e
p
ra
n
d
om
va
ri
ab
le
in
eq
u
at
io
n
(1
5)
of
W
eb
A
p
p
en
d
ix
D
;
2
.
T
h
e
p
-v
a
lu
e
of
B
F
w
it
h
in
fo
rm
a
ti
v
e
p
ri
or
is
ca
lc
u
la
te
d
b
a
se
d
on
th
e
n
u
ll
d
is
tr
ib
u
ti
on
of
2l
og
(B
F
)
of
χ
2
(3
);
3.
R
an
k
in
g
of
ge
n
es
a
cc
o
rd
in
g
to
S
K
A
T
(s
ee
S
ec
ti
on
5)
;
4.
R
an
k
in
g
of
ge
n
es
a
cc
o
rd
in
g
to
th
e
B
u
rd
en
te
st
(s
ee
S
ec
ti
on
5)
;
5.
R
an
k
in
g
of
ge
n
es
a
cc
o
rd
in
g
to
S
K
A
T
-O
(s
ee
S
ec
ti
on
5)
;
6.
R
an
k
in
g
of
ge
n
es
a
cc
o
rd
in
g
to
B
F
w
it
h
n
on
-i
n
fo
rm
at
iv
e
p
ri
or
as
sh
ow
n
in
eq
u
at
io
n
(1
5)
in
W
eb
A
p
p
en
d
ix
D
.
26
Supplementary Materials for A Bayes Factor
Approach with Informative Prior for Rare Genetic
Variant Analysis from Next Generation Sequencing
Data
Jingxiong Xu1,2, Wei Xu1,3, Laurent Briollais1,2
1 Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
2 Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
3 Princess Margaret Cancer Center, Toronto, Canada
1 Web Appendix A: Rare variant count distribu-
tion for the gene CHEK2
2 Web Appendix B: Fit of the the beta-binomial
distribution to the simulated and WES lung can-
cer data
To check the fit of the beta-binomial distribution, we compare the model-based overall
RV rate ηˆ to the mean RV rate (across all individuals) 1
N
∑
j,k
xjk
n
using both the
simulated data and Toronto WES lung cancer data (see Figures 2 and 3). Our
simulation studies and real data analysis showed that the beta-binomial distribution
provided a very good fit of the sequencing RV data.
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Figure 1: Distribution of RV proportion in cases and controls for the gene CHEK2.
Proportion of RV pˆ = x
n
is calculated for each individual, where x is the total RV
count, n is the number of sites in the region.
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Figure 2: Scatter plots comparing ηˆ estimated by the beta-binomial model used in
the BF derivation (y-axis) and the mean of RV rates (x/n) across individuals (x-axis).
Under each simulation scenario with different gene sizes and sample sizes, the plot is
based on 1000 genes simulated under H0 (See Section 5 in the main manuscript). The
scatter points close to 45 degree line indicate that the model-based RV rate estimate
and mean RV rate are consistent across genes. Besides, it shows that the mean RV
rate has larger variation when the gene size is small, compared with scenario where
gene size is large.
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Figure 3: Scatter plot comparing ηˆ estimated by the beta-binomial model used in the
BF derivation (y-axis) and the mean of RV rates (x/n) across individuals (x-axis).
This result is based on the Toronto lung cancer WES data. The scatter points close
to 45 degree line indicate that the model-based RV rate estimate and mean RV rate
are consistent across genes.
3 Web Appendix C: Estimation of correlation be-
tween RVs within the same gene/region.
The results showed in Figure 4 below demonstrate that the beta-binomial distribution
used in the derivation of the BF accounts for correlation between RVs within the same
gene/region and that this model-based estimate of the intra-class correlation is close to
some average correlation estimate between pairs of variants obtained with a Pearson
correlation coefficient.
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Figure 4: Comparison between the intra-class correlation (ICC) estimated by the
beta-binomial distribution used in the BF derivation (log scale on x-axis) and the
mean Pearson correlation (r2) between pairs of variants within the same gene (log
scale on y-axis). This result is based on 500 simulated genes, with a number of
sites varying from 20 to 974. The model-based ICC is estimated by 1
Kˆ+1
, where Kˆ
is the MLE of the precision parameter K in the beta prior distribution based on
the marginal likelihood (see section 3.3 in the main manuscript). The scatter points
close to 45 degree line indicate that the model-based ICC and Pearson correlation
coefficient are consistent across genes.
5
4 Web Appendix D: Proof of Theorem 1
In equation (??) of the main manuscript, we showed that assuming a beta prior, the
marginal likelihood of the data under H0 is proportional to the integral function
m0(X|K˜, η∗, K∗) ∝ I =
∫ 1
0
∏2
j=1
∏Nj
k=1B{xjk + K˜η, njk − xjk + K˜(1− η)}
B{K˜η, K˜(1− η)}N pi(η|η
∗, K∗)dη.
(1)
According to equation (5) in Kass and Raftery (1995), this integral can be ap-
proximated using Laplace’s method by
IˆMLE = (2pi)
1/2Σˆ1/2Pr(X|ηˆ)pi(ηˆ|η∗, K∗), (2)
where Pr(X|η) =
∏2
j=1
∏Nj
k=1B{xjk+K˜η,njk−xjk+K˜(1−η)}
B{K˜η,K˜(1−η)}N is the likelihood function, ηˆ
is the MLE of η based on this likelihood and Σˆ is the estimated variance of ηˆ with
Σˆ = {−d2 logPr(X|η)
dη2
}−1|η=ηˆ, where ηˆ ∼ N(η0, Σˆ). As N →∞,
I = IˆMLE{1 +O(N−1)}.
When K∗η∗ → ∞ and η∗ → 0, we have K∗(1 − η∗) → ∞, K∗ → ∞ and log(1 −
η∗) → 0, therefore, by using stirling’s series of log Γ(K∗η∗), log Γ{K∗(1 − η∗)} and
log Γ(K∗) (Impens, 2003), log pi(η|η∗, K∗)
∣∣∣
η=ηˆ,η∗=ηˆ
can be written as
log pi(η|η∗, K∗)
∣∣∣
η=ηˆ,η∗=ηˆ
= log
ηK
∗η∗−1(1− η)K∗(1−η∗)−1
B{K∗η∗, K∗(1− η∗)}
∣∣∣
η=ηˆ,η∗=ηˆ
= (K∗η∗ − 1) log η + {K∗(1− η∗)− 1} log(1− η)− log
√
2pi
−(K∗η∗ − 1
2
) log(K∗η∗)− (K∗ −K∗η∗ − 1
2
) log(K∗ −K∗η∗)
+(K∗ − 1
2
) logK∗ −O( 1
K∗η∗
)−O{ 1
K∗(1− η∗)}+O(
1
K∗
)
∣∣∣
η=ηˆ,η∗=ηˆ
= −1
2
log ηˆ +
1
2
logK∗ − log
√
2pi − 1
2
log(1− ηˆ),
= −1
2
log ηˆ +
1
2
logK∗ − log
√
2pi.
Thus, by taking η∗ = ηˆ,
log IˆMLE ≈ 1
2
log(2pi) +
1
2
log Σˆ + logPr(X|ηˆ)− 1
2
log ηˆ +
1
2
logK∗ − log
√
2pi,
≈ 1
2
log Σˆ + logPr(X|ηˆ)− 1
2
log ηˆ +
1
2
logK∗. (3)
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Besides, in equation (??) of the main manuscript, it is shown that under a beta
prior, the marginal likelihood function under H1 is proportional to a product of two
integral functions:
m1(X|K˜, η∗1, K∗1 , η∗2, K∗2) ∝
2∏
j=1
∫ 1
0
∏Nj
k=1 B{xjk + K˜η, njk − xjk + K˜(1− η)}
B{K˜η, K˜(1− η)}Nj
ηK
∗
j η
∗
j−1(1− η)K∗j (1−η∗j )−1
B{K∗j η∗j , K∗j (1− η∗j )}
dη,
=I1 × I2.
(4)
Similar to IˆMLE, by assuming η
∗
1 = ηˆ1, η
∗
2 = ηˆ2 and using Laplace’s approximation,
we have
Iˆ1MLE = (2pi)
1/2Σˆ1
1/2
Pr(X1|ηˆ1)pi(ηˆ1|ηˆ1, K∗1),
and
Iˆ2MLE = (2pi)
1/2Σˆ2
1/2
Pr(X2|ηˆ2)pi(ηˆ2|ηˆ2, K∗2),
with Σˆ1 = {−d2 logPr(X1|η1)dη21 }
−1|η1=ηˆ1 and Σˆ2 = {−d
2 logPr(X2|η2)
dη22
}−1|η2=ηˆ2 .
As N1 →∞, I1 = Iˆ1MLE{1 +O(N−11 )} and as N2 →∞, I2 = Iˆ2MLE{1 +O(N−12 )}.
Therefore, similar to equation (3), we have
log Iˆ1MLE ≈
1
2
log Σˆ1 + logPr(X1|ηˆ1)− 1
2
log ηˆ1 +
1
2
logK∗1 ,
and
log Iˆ2MLE ≈
1
2
log Σˆ2 + logPr(X2|ηˆ2)− 1
2
log ηˆ2 +
1
2
logK∗2 .
The BF is then given by
BF =
m1(X|K˜, η∗1, K∗1 , η∗2, K∗2)
m0(X|K˜, η∗, K∗)
≈ Iˆ1MLE × Iˆ2MLE
IˆMLE
. (5)
The last equality comes from the fact that the term before the integral in equation
(??) and (??) of the main manuscript cancels out.
7
Let the parameters K∗ = p2ηˆΣˆ−1, K∗1 = ηˆ1Σˆ
−1
1 , K
∗
2 = ηˆ2Σˆ
−1
2 , then we have
logBF ≈ log Iˆ1MLE + log Iˆ2MLE − log IˆMLE,
≈1
2
(
− log ηˆ1
Σˆ1
− log ηˆ2
Σˆ2
+ log
ηˆ
Σˆ
)
+
1
2
log
K∗1K
∗
2
K∗
− logPr(X1|ηˆ)− logPr(X2|ηˆ)
+ logPr(X1|ηˆ1) + logPr(X2|ηˆ2)− log(p),
≈ logPr(X1|ηˆ1) + logPr(X2|ηˆ2)− logPr(X1|ηˆ)− logPr(X2|ηˆ)− log(p).
(6)
Expanding the log-likelihood function around η0, the true value of η, according to
Taylor’s expansion, we have
logPr(X1|ηˆ1) = logPr(X1|η0) + (ηˆ1 − η0)`′1(η0) +
1
2
(ηˆ1 − η0)2`′′1(η0) + o(ηˆ1 − η0)2,
logPr(X2|ηˆ2) = logPr(X2|η0) + (ηˆ2 − η0)`′2(η0) +
1
2
(ηˆ2 − η0)2`′′2(η0) + o(ηˆ2 − η0)2,
logPr(X1|ηˆ) = logPr(X1|η0) + (ηˆ − η0)`′1(η0) +
1
2
(ηˆ − η0)2`′′1(η0) + o(ηˆ − η0)2,
logPr(X2|ηˆ) = logPr(X2|η0) + (ηˆ − η0)`′2(η0) +
1
2
(ηˆ − η0)2`′′2(η0) + o(ηˆ − η0)2,
(7)
where `′(η0) ≡ d logPr(X|η)dη |η=η0 , `′1(η0) ≡ d logPr(X1|η)dη |η=η0 , `′2(η0) ≡ d logPr(X2|η)dη |η=η0 ,
`′′(η0) ≡ d2 logPr(X|η)dη2 |η=η0 , `′′1(η0) ≡ d
2 logPr(X1|η)
dη2
|η=η0 and `′′2(η0) ≡ d
2 logPr(X2|η)
dη2
|η=η0
and the approximation error term o() can be ignored.
From equation (20) in Web Appendix H, we have the following approximation
(ηˆ1 − η0)`′′1(η0) ≈ −(ηˆ1 − η0)Σ−11 ≈ −`′1(η0) and (ηˆ2 − η0)`′′2(η0) ≈ −(ηˆ2 − η0)Σ−12 ≈
−`′2(η0). In equation (7) we then have
(ηˆ1 − η0)`′1(η0) + (ηˆ2 − η0)`′2(η0)− (ηˆ − η0)`′1(η0)− (ηˆ − η0)`′2(η0)
=(ηˆ1 − ηˆ)`′1(η0) + (ηˆ2 − ηˆ)`′2(η0),
≈(ηˆ1 − ηˆ)(ηˆ1 − η0)Σ−11 + (ηˆ2 − ηˆ)(ηˆ2 − η0)Σ−12 ,
using ηˆ ≈ ηˆ1Σ2+ηˆ2Σ1
Σ1+Σ2
from Proposition 1, this yields
≈ (ηˆ1 − ηˆ2)
(Σ1 + Σ2)
(ηˆ1 − η0)− (ηˆ1 − ηˆ2)
(Σ1 + Σ2)
(ηˆ2 − η0),
≈ (ηˆ1 − ηˆ2)
2
(Σ1 + Σ2)
.
(8)
8
Based on a similar derivation using proposition 1, we have
1
2
(ηˆ1 − η0)2`′′1(η0) +
1
2
(ηˆ2 − η0)2`′′2(η0)−
1
2
(ηˆ − η0)2`′′1(η0)−
1
2
(ηˆ − η0)2`′′2(η0)
≈− (ηˆ1 − ηˆ2)
2
2(Σ1 + Σ2).
(9)
From equations (6) and (7), we know that 2 logBF can be written as
2 logBF ≈ (ηˆ1 − ηˆ2)
2
Σ1 + Σ2
− 2log(p), (10)
where (ηˆ1−ηˆ2)
2
Σ1+Σ2
d−→ χ2(1).
Since under H0, p ∼ Unif(0, 1), thus −2log(p) ∼ χ2(2) , which we assumed indepen-
dent of (ηˆ1−ηˆ2)
2
Σ1+Σ2
. Indeed, the correlation coefficient between these two components is
empirically evaluated based on the lung cancer WES data (see Figures 8 and 10) and
the simulated data (see Figure 9), and was found very small. Therefore,
2 logBF
d−→ χ2(3). (11)
When the number of p-values from the KS test was less than 5, we assumed a
non-informative prior probability p = 1 for the BF.
The derivation of the asymptotic distribution of the BF above requires the as-
sumptions that K∗ and K∗η∗ be large. In Web Appendix O, we checked that these
assumptions are realistic based on our simulation results.
5 Web Appendix E: Assessment of the Laplace ap-
proximation
In this section, the performance of the Laplace’s approximation is assessed from the
simulated data. First, we compared the integrand function to the approximated
normal density function; Second, we compared the Laplace’s estimate to a Monte
Carlo estimate.
5.1 Comparison of the integrand function
According to equation (1) of the Web Appendix, we have
9
I =
∫ 1
0
∏2
j=1
∏Nj
k=1B{xjk + K˜η, njk − xjk + K˜(1− η)}
B{K˜η, K˜(1− η)}N pi(η|η
∗, K∗)dη.
=
∫ +∞
−∞
∏2
j=1
∏Nj
k=1B(xjk + K˜η, njk − xjk + K˜(1− η))
B(K˜η, K˜(1− η))N
ηK
∗η∗−1(1− η)K∗(1−η∗)−1
B(K∗η∗, K∗(1− η∗))
η(1− η)
∣∣∣∣
η= e
θ
1+eθ
dθ,
=
∫ +∞
−∞
f(θ)dθ.
(12)
Applying Laplace approximation, we first find θˆ, s.t.f(θˆ) = max f(θ),
f(θ) ≈ g(θ) = f(θˆ)σ
√
2piφ(θ;µ, σ2)
where φ(.) is Normal density function with parameter µ = θˆ, σ2 = − 1
`′′(θˆ)
. We
then draw two curves: log f(θ) and log g(θ) in Figure 5 to examine the similarity of
these two functions.
Figure 5 shows that we have a very good approximation of the likelihood function
for values of θ = log(η/(1 − η)) in the range of -6.9 to -5.5, which corresponds to η
values in the range of 0.001 to 0.004. Most of the estimated η values in our real data
application lie in this interval (see Figure 3 of the Web Appendix).
5.2 Monte Carlo Estimate of the integral function
According to equation (1), we have
I =
∫ 1
0
∏2
j=1
∏Nj
k=1 B{xjk + K˜η, njk − xjk + K˜(1− η)}
B{K˜η, K˜(1− η)}N pi(η|η
∗, K∗)dη. (13)
where pi(η; k∗, η∗) is the density function of Beta distribution.
The simplest Monte Carlo integration estimate of the above formula is∫ 1
0
∏2
j=1
∏Nj
k=1B{xjk + K˜η, njk − xjk + K˜(1− η)}
B{K˜η, K˜(1− η)}N pi(η|η
∗, K∗)dη
≈ 1
L
L∑
l=1
∏2
j=1
∏Nj
k=1 B(xjk + K˜ηl, n− xjk + K˜(1− ηl))
B(K˜ηl, K˜(1− ηl))N
,
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Figure 5: Integrand function approximation. Red curve represents log g(θ), and blue
curve represents log f(θ).
where {ηl, l = 1, ..., L} are Monte Carlo samples generated from the distribution of
η, Beta(η∗, K∗).
To assess the accuracy of Laplace method, we compared the Laplace estimate to
10 Monte Carlo estimates. Figure 6 and 7 (zoomed-in version) show that the BF
computed by the Laplace method is very close to the mean of the BF computed by
the Monte Carlo approximations. The former method is a more efficient and accurate
approach compared to the latter.
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6 Web Appendix F: Derivation of BF with mix-
ture prior
6.1 Compare η1 and η2 with fixed w0j (w0j ≡ w˜0) and fixed K
(K ≡ K˜)
The parameters w˜0 and K˜ are obtained by MLE, from the whole sample under the
null hypothesis. We can formulate the null and alternative hypotheses as:
H0 : η1 = η2 = η
H1 : η1 6= η2
The marginal likelihood under H0 is
m0(X|w˜0, K˜, η∗, K∗) =
∫
η
∫
P
f(X|P)g(P|η, w˜0, K˜)dPpi(η|η∗, K∗)dη,
where∫
P
f(X|P)g(P|η, w˜0, K˜)dP =
2∏
j=1
Nj∏
k=1
∫
pjk
f(xjk|pjk)g(pjk|η, w˜0, K˜)dpjk,
=
∏
xjk=0
h0(w˜0, η, K˜)
∏
xjk>0
h1(xjk, w˜0, η, K˜).
(14)
We have
h0(w˜0, η, K˜) =h0(w˜0, η, K˜|pjk = 0)P (pjk = 0) + h0(w˜0, η, K˜|pjk > 0)P (pjk > 0),
=E{f(xjk = 0|pjk = 0)}P (pjk = 0) + (1− w˜0)
∫ 1
0
p0jk(1− pjk)njkg(pjk|η, K˜)dpjk,
=1× P (pjk = 0) + (1− w˜0)B{ηK˜, K˜(1− η) + njk}
B{ηK˜, K˜(1− η)}
∫ 1
0
pηK˜−1jk (1− pjk)K˜(1−η)+njk−1
B{ηK˜, K˜(1− η) + njk}
dpjk,
=w˜0 + (1− w˜0)B{ηK˜, K˜(1− η) + njk}
B{ηK˜, K˜(1− η)} ,
13
and
h1(xjk, w˜0, η, K˜) =h1(xjk, w˜0, η, K˜|pjk = 0)w˜0 + h1(xjk, w˜0, η, K˜|pjk > 0)(1− w˜0),
=(1− w˜0)
∫ 1
0
(
njk
xjk
)
p
xjk
jk (1− pjk)njk−xjk
pηK˜−1jk (1− pjk)K˜(1−η)−1
B{ηK˜, K˜(1− η)} dpjk,
=(1− w˜0)
(
njk
xjk
)
B(ηK˜ + xjk, K˜(1− η) + njk − xjk)
B{ηK˜, K˜(1− η)}∫ 1
0
p
ηK˜+xjk−1
jk (1− pjk)K˜(1−η)+njk−xjk−1
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
dpjk,
=(1− w˜0)
(
njk
xjk
)
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
B{ηK˜, K˜(1− η)} .
Therefore,
m0(X|w˜0, K˜, η∗, K∗) =
∫
η
f(X|w˜0, η, K˜)pi(η|η∗, K∗)dη,
=
∫
η
∏
xjk=0
[
w˜0 + (1− w˜0)B{ηK˜, K˜(1− η) + njk}
B{ηK˜, K˜(1− η)}
]
×
∏
xjk>0
[
(1− w˜0)
(
njk
xjk
)
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
B{ηK˜, K˜(1− η)}
]
pi(η|η∗, K∗)dη,
(15)
and
m1(X|w˜0, K˜, η∗1, K∗1 , η∗2, K∗2) =
2∏
j=1
∫
η
f(X|w˜0, η, K˜)pi(η|η∗, K∗)dη,
=
2∏
j=1
∫
η
∏
xjk=0
[
w˜0 + (1− w˜0)B{ηK˜, K˜(1− η) + njk}
B{ηK˜, K˜(1− η)}
]
×
∏
xjk>0
[
(1− w˜0)
(
njk
xjk
)
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
B{ηK˜, K˜(1− η)}
]
pi(η|η∗j , K∗j )dη.
(16)
The marginal likelihood is computed using Laplace approximation, see equation
(2). The MLE of η can be expressed as ηˆ = argmax
η
{log f(X|η, w˜0, K˜)}, where
14
f(X|η, w˜0, K˜) =
∫
P
f(X|P)g(P|η, w˜0, K˜)dP. The estimates of η1 and η2 are ob-
tained in a similar way by the MLE computed separately in controls and cases,
but assuming the same w˜0 and K˜, i.e. ηˆ1 = argmax
η
{log f(X1|η, w˜0, K˜)} and ηˆ2 =
argmax
η
{log f(X2|η, w˜0, K˜)}. The parameters in the hyperprior distribution are de-
fined in a similar way as indicated at the end of Section 3.4.1 of the main manuscript
under a non-informative prior setting.
6.2 Compare both η1, w01 and η2, w02 with fixed K (K ≡ K˜)
The parameter K˜ is obtained by MLE, from the whole sample. For this comparison,
the null and alternative hypotheses can be written as
H0 : η1 = η2 = η and w01 = w02 = w0
H1 : η1 6= η2 or w01 6= w02
In our simulations and real data analysis, this BF formulation did not result in
improved power compared to the other versions so the results with this approach are
omitted in these sections.
To simplify the derivation, we assume njk ≡ n, when xjk = 0.
The marginal likelihood under H0 is
m0(X|K˜, η∗, K∗, η∗∗, K∗∗) =
∫
f(X|P)g(P)dP,
=
∫
P
f(X|P)
∫
η
∫
w0
g(P|η, w0, K˜)pi(w0|η∗∗, K∗∗)pi(η|η∗, K∗)dw0 dη dP,
=
∫
η
∫
w0
∫
P
f(X|P)g(P|η, w0, K˜)dP pi(w0|η∗∗, K∗∗)pi(η|η∗, K∗)dw0 dη,
where
∫
w0
∫
P
f(X|P)g(P|w0)dPpi(w0)dw0 is the integral of equation (14) in terms of
w0. Suppose Z ≡ B(ηK˜,K˜(1−η)+n)B(ηK˜,K˜(1−η)) ,
∫
w0
∫
P
f(X|P)g(P|w0)dPpi(w0)dw0 can be written
as
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∫
w0
∫
P
f(X|P)g(P|w0)dPpi(w0)dw0 =
∏
xjk>0
[(
njk
xjk
)
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
B(ηK˜, K˜(1− η))
]
1
B(η∗∗K∗∗,K∗∗(1− η∗∗))
×
∫ 1
0
[(M
0
)
(1− w0)MZM +
(
M
1
)
w0(1− w0)M−1ZM−1 + ...+
(
M
M
)
wM0
]
× wη∗∗K∗∗−10 (1− w0)N−M+K
∗∗(1−η∗∗)−1dw0
=
∏
xjk>0
[(
njk
xjk
)
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
B(ηK˜, K˜(1− η))
]
1
B(η∗∗K∗∗,K∗∗(1− η∗∗))
M∑
h=0
[(
M
h
)
ZM−hB{h+ η∗∗K∗∗,−h+N +K∗∗(1− η∗∗)}
×
∫ 1
0
wh+η
∗∗K∗∗−1
0 (1− w0)−h+N+K
∗∗(1−η∗∗)−1
B{h+ η∗∗K∗∗,−h+N +K∗∗(1− η∗∗)}dw0
]
=
∏
xjk>0
[(
njk
xjk
)
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
B(ηK˜, K˜(1− η))
]
1
B(η∗∗K∗∗,K∗∗(1− η∗∗)) ×
M∑
h=0
[(
M
h
)
B{ηK˜, K˜(1− η) + n}M−h
B{ηK˜, K˜(1− η)}M−h
×B{h+ η∗∗K∗∗, N − h+K∗∗(1− η∗∗)}
]
.
where M denotes the number of individuals with 0 rare variants for the specific gene
(see Section 3.4.2 in the main manuscript).
Therefore,
m0(X|K˜, η∗, K∗, η∗∗, K∗∗) =
∏
xjk>0
(
njk
xjk
)
1
B{η∗∗K∗∗, K∗∗(1− η∗∗)}∫
η
∏
xjk>0
[
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
B{ηK˜, K˜(1− η)}
]
×
M∑
h=0
[(
M
h
)
B{ηK˜, K˜(1− η) + n}M−h
B{ηK˜, K˜(1− η)}M−h
B{h+ η∗∗K∗∗, N − h+K∗∗(1− η∗∗)}
]
× pi(η|η∗, K∗)dη
(17)
16
and
m1(X|K˜, η∗1, K∗1 , η∗2, K∗2 , η∗∗1 , K∗∗1 , η∗∗2 , K∗∗2 ) =
2∏
j=1
∏
xjk>0
(
njk
xjk
)
1
B{η∗∗j K∗∗j , K∗∗j (1− η∗∗j )}
×
2∏
j=1
∫
η
∏
xjk>0
[
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
B{ηK˜, K˜(1− η)}
]
×
M∑
h=0
[(
M
h
)
B{ηK˜, K˜(1− η) + n}M−h
B{ηK˜, K˜(1− η)}M−h
B{h+ η∗∗j K∗∗j , N − h+K∗∗j (1− η∗∗j )}
]
× pi(η|η∗j , K∗j )dη
(18)
As before, η is estimated by MLE as ηˆ = argmax
η
{log f(X|η, K˜, η∗∗, K∗∗)} and ηj
is estimated by ηˆj = argmax
η
{log f(Xj|η, K˜, η∗∗j , K∗∗j )}, where
f(X|η, K˜, η∗∗, K∗∗) =
∏
xjk>0
[
B{ηK˜ + xjk, K˜(1− η) + njk − xjk}
B{ηK˜, K˜(1− η)}
]
×
M∑
h=0
[(
M
h
)
B{ηK˜, K˜(1− η) + n}M−h
B{ηK˜, K˜(1− η)}M−h
B{h+ η∗∗K∗∗, N − h+K∗∗(1− η∗∗)}
]
.
(19)
7 Web Appendix G: Correlation assessment be-
tween the two components of the BF with infor-
mative prior
First, the scatter plots in Figure 8 illustrate that the two components of informa-
tive BF statistic in the lung cancer WES data are uncorrelated, under both a beta
and a mixture prior. Besides, to assess the correlation between the BF with non-
informative prior and the KS test p-value, we compute the Kendall rank correlation
coefficient, which does not rely on the distribution assumption of each component, in
the simulated data (Figure 9) and lung cancer WES data (Figure 10).
It is noteworthy that here we evaluate the correlation between two components of
informative BF statistic under H0. It is under this assumption that the majority of
17
Figure 8: Scatter plot of the two BF components with x-axis: (ηˆ1−ηˆ2)
2
Σ1+Σ2
and y-axis:
−2log(p) given in equation (10), based on all the genes from the lung cancer WES
study. The Kendall correlation coefficient between the 2 components is 0.03 for beta
prior and 0.04 for mixture prior.
genes in the lung cancer WES study are non associated with the disease status. To
avoid the influence of linkage disequilibrium (LD) across RVs from the same gene on
the correlation assumption of the two components, we did prune highly correlated RVs
to compute the KS test p-values. Even if we notice some slightly higher correlation
between the two components of BF statistics for smaller genes, we do not observe an
increase in type I error for these genes in our simulation results (Table 1 of the main
manuscript). Therefore, the independence assumption between the two components
of the informative BF can be justified by the fact that they are almost uncorrelated
in our simulations and real data.
8 Web Appendix H: Proof of Proposition 1
Expanding the derivatives around η0 using Taylor series expansion, assuming `1 is
3 times differentiable on the closed interval between η0 and ηˆ1 and closed interval
between η0 and ηˆ; `2 is 3 times differentiable on the closed interval between η0 and
ηˆ2 and closed interval between η0 and ηˆ, we obtain
18
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Figure 9: Distribution of Kendall correlation coefficient between (ηˆ1−ηˆ2)
2
Σ1+Σ2
and −2log(p)
under the null hypothesis for the BF with beta prior with respect to different gene
sizes and sample sizes. The KS test p-values are computed after pruning highly
correlated variants (Pearson correlation coefficient > 0.5). For all simulation scenar-
ios, the Kendall correlation coefficient is close to zero, justifying our assumption of
independence between the two components of the informative BF statistic under H0.
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Figure 10: Distribution of Kendall correlation coefficient between (ηˆ1−ηˆ2)
2
Σ1+Σ2
and
−2log(p) for the BF with beta prior with respect to gene sizes in the lung cancer
WES study. The KS test p-values used for this result are computed after pruning
highly correlated variants (Pearson correlation coefficient > 0.5).
Table 1: Average Kendall rank correlation coefficient estimated from the WES Lung
Cancer study based on 1000 selected genes
#(sites)
All the genes [20, 30) [30, 60) [60, 100) [100, 17067]
Beta prior
r2 > 0.99∗ 0.03 0.05 0.01 0.03 0.04
r2 > 0.5∗ 0.03 0.06 0.01 0.04 0.02
Mixture prior
r2 > 0.99∗ 0.04 0.05 0.01 0.07 0.02
r2 > 0.5∗ 0.03 0.06 0.01 0.06 0.01
∗ Highly correlated RVs are removed for the KS test based on either r2 > 0.5 or r2 > 0.99.
20
`′1(ηˆ1) = `
′
1(η0) + (ηˆ1 − η0)`′′1(η0) + (ηˆ1 − η0)2
`′′′1 (η10)
2
for η10 between η0 and ηˆ1,
`′2(ηˆ2) = `
′
2(η0) + (ηˆ2 − η0)`′′2(η0) + (ηˆ2 − η0)2
`′′′2 (η20)
2
for η20 between η0 and ηˆ2,
`′1(ηˆ) = `
′
1(η0) + (ηˆ − η0)`′′1(η0) + (ηˆ − η0)2
`′′′1 (η01)
2
for η01 between η0 and ηˆ,
`′2(ηˆ) = `
′
2(η0) + (ηˆ − η0)`′′2(η0) + (ηˆ − η0)2
`′′′2 (η02)
2
for η02 between η0 and ηˆ.
(20)
Since we have `′1(ηˆ1) = 0, `
′
2(ηˆ2) = 0 and `
′(ηˆ) = `′1(ηˆ) + `
′
2(ηˆ) = 0, we deduct that
`′1(η0) + `
′
2(η0) = −(ηˆ1 − η0)`′′1(η0)− (ηˆ2 − η0)`′′2(η0) + o(ηˆ1 − η0) + o(ηˆ2 − η0)
and
`′1(η0) + `
′
2(η0) = −(ηˆ − η0)`′′1(η0)− (ηˆ − η0)`′′2(η0) + o(ηˆ − η0)
=⇒ (ηˆ1 − ηˆ)Σ−11 + (ηˆ2 − ηˆ)Σ−12 = o(ηˆ1 − η0) + o(ηˆ2 − η0) + o(ηˆ − η0),
=⇒ ηˆ = ηˆ1Σ2+ηˆ2Σ1
Σ1+Σ2
+ o(ηˆ1 − η0) + o(ηˆ2 − η0) + o(ηˆ − η0).
Since Σ−1 = Σ−11 + Σ
−1
2 , ignoring the approximation error term, we deduct that
Σ = Σ1Σ2
Σ1+Σ2
.
9 Web Appendix I: BFDR procedure for genome-
wide inference
For the computation of vi in the BFDR procedure, we need to specify p(pi0|Y ) as
outlined in equation (6) of the main manuscript. Following Scott and Berger (2006),
we can assume a beta prior distribution for pi0, the proportion of non-associated genes,
as
f(pi0|Y ) = (α + 1)piα0 . (21)
For this prior distribution of pi0, we need a specification of α parameter. For α, a
large parameter value corresponds to a large proportion of genes not associated with
the response (case-control status), which leads to a more stringent gene selection at
the genome-wide level. We need to emphasize that the BF procedure is sensitive to
this hyperparameter specification, in particular, the choice of hyperparameters should
21
be different for the BF with and without informative priors. The reason is that the
BF distribution that is needed to compute the component Pr(Zi = 1|Y, pi0) in equa-
tion (7) of the main manuscript, is quite different when using informative prior or
not.
For the specification of the above hyperparameters and thus to estimate vi, we
propose the following two-step procedure.
1. We first estimate pi0, based on the approach proposed by Wen (2017) for both the
BF with and without informative prior. Both estimates can be different since
the distribution of the two BFs and also their theoretical null distributions can
differ.
2. Based on pˆi0, estimated in step 1, we decide the hyperparamter α in equation
(21). The choice of the hyperparameter α also depends on whether informative
prior is incorporated in the BF or not.
For step 1, Wen (2017) showed that we can obtain an upper bound estimator of
pi0 by
pˆi0 =
∑m
i=1 I(BFi ≤ qi,γ)
mγ
,
where qi,γ denotes the γ-quantile of the BFi under H0, i.e. F
0
i (qi,γ) = γ, where F
0
i (x)
is the c.d.f. of the BF under H0. A problem with Wen’s procedure, however, is that
F 0i (x) is not known and would need to be estimated empirically, for example from
permutation sampling, which could be intractable if the number of tests (i.e., genes)
is large. However, from our theoretical results, we know that 2 logBFi
d−→ χ2(1) or
2 logBFi
d−→ χ2(3) under a non-informative or informative prior, respectively. We can
then replace the estimator of pi0 by
pˆi0 =
∑m
i=1 I(2 logBFi ≤ q∗γ)
mγ
, (22)
where q∗γ is the γ-quantile of a χ
2(1) distribution for non-informative prior and χ2(3)
distribution for informative prior. The choice of γ results from a tradeoff between
bias and variance of pˆi0 (Storey and Tibshirani, 2003; Efron, 2010; Wen, 2017). In
the genome-wide analysis, there is a high proportion of non associated genes with
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BF values close to 1 (more than expected under the null), which could be due to
the high proportion of small genes (20-50 sites per gene) that can be sensitive to
gentoyping error and data pre-processing. As the number of genes is large in a WES
study (> 10, 000), the proportion of truly associated genes (1− pˆi0) is expected to be
small (≈ 0.1%). Therefore, we chose a γ value close to 1 in our real data application.
At the end of step 1, we will have an estimate of pi0 for the BF with non-informative
and with informative prior, that we denote respectively pˆi0 and pˆi0inf .
For the second step of our BFDR procedure, we need to specify α in the prior
distribution of pi0 above. For the BF with non informative prior, the hyperparameter
estimate αˆ is determined based on pˆi0 obtained from Step 1 by letting the expectation
of the prior distribution equal to pˆi0,
E(pi0) =
α
α + 1
= pˆi0 ⇒ αˆ = pˆi0
1− pˆi0 . (23)
For the BF with informative prior, we use the following strategy to determine this
hyperparameter that we denote αinf .
For a given gene i, we can deduct from equation 10 the relationship between the
BF with and without informative prior as
BFi,inf = BFi/pi, (24)
where BFi,inf is the BF statistic with informative prior, BFi is BF with non infor-
mative prior and pi the p-value from the KS test .
For the BF with informative prior, we write the probability f(pi0|Y ) as
f(pi0|Y ) = (αinf + 1)(pi0inf )αinf , (25)
and the expression (7) of the main manuscript as
Pr(Zi = 1|Y, pi0inf ) = (1− pi0inf )BFi/pi
pi0inf + (1− pi0inf )BFi/pi . (26)
We assume that under H0, incorporating informative prior into BF should not
change vi very much, in other words, Pr(Zi = 1|Y, pi0) based on non-informative
prior and Pr(Zi = 1|Y, pi0inf ) based on informative prior should be similar.
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Therefore, for gene i, we need to satisfy
E
(
(1− pi0inf )BFi/pi
pi0inf + (1− pi0inf )BFi/pi
)
= E
(
(1− pi0)BFi
pi0 + (1− pi0)BFi
)
. (27)
Assuming pi0 → 1 and pi0inf → 1, this leads to
E((1− pi0inf )/pi) = E(1− pi0)⇔ E(pi0inf ) = 1− pi(1− E(pi0)). (28)
Equation (28) can then be written as
αinf
αinf + 1
=1− pi(1− α
α + 1
)
=
α + 1− pi
α + 1
=
α+1
pi
− 1
α+1
pi
.
Thus, since α 1 and α/p0  1, we have
αinf ≈ α + 1
pi
− 1 ≈ α
pi
. (29)
Let’s define α0inf ≡ αpi . As stated above, for single gene analysis, using α0inf for
BF with informative prior would lead to similar estimate of vi using BF with non-
informative prior. However, in the genome-wide inference, the hyperparameter αinf
has to be same across all the genes, so we replace pi with a fixed value p0 in equation
(29). Accordingly, we can determine an estimator of the hyperparameter αinf as
αˆinf =
αˆ
p0
. (30)
The determination of p0 in equation (30) can be based on matching the expected
number of associated genes m(1− pˆi0inf ). In particular, we propose
p0 ≡ p(1−pˆi0inf ), (31)
where p(1−pˆi0inf ) is the (1− pˆi0inf )-quantile of the KS test p-value distribution. There-
fore, for gene i with lowest KS p-values, p0 > pi leads to having αˆinf < α0inf , i.e.
larger estimate of vi compared to using non-informative prior. Otherwise, for the
genes with p0 < pi, it leads to a more conservative (smaller) estimate of vi compared
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to using non-informative prior. We show in Figure 11 that the proposed procedure
adjusts well the vˆi distribution in our simulated data when using the BF with infor-
mative prior. For instance, Figure 11.b shows the distribution of vˆi obtained using
αˆ instead of αˆinf to calculate BFDR. A lot of genes have vˆi values between 0.8 and
0.99 and for which the null hypothesis of no association could be rejected (i.e. genes
declared associated). This problem does not happen when using αˆinf as shown in
11.c, where there is a better separation between small and high values of vˆi.
10 Web Appendix J: QQ plot of the BF with in-
formative prior under H0
11 Web Appendix K: Type I error rate and power
comparison between BF and existing methods
Figure 13, 14, 15 and 16 are graphical representation of type I error and power
results for the BF and other competing methods shown in Tables 1 & 2 of the main
manuscript.
Besides, we repeated our complete simulation runs 6 times for the BF (Section
5 of main manuscript) so that we obtained a range of type I error rates and power
rates under each scenario considered. Our simulation results, presented in Tables 1
and 2 of the main manuscript, fall within the range of the results obtained over the
complete simulation runs. For the type I error rates, we noticed a higher variability
for small sample sizes (N=500) when the number of sites ≤ 45. We also observed a
slight increased in the empirical type I error when the number of sites is very large,
i.e. > 145. For the range of power rates, the variability decreases with the sample
size and to some extent with the number of sites.
12 Web Appendix L: Simulation results for large
genes
In the the WES real data application, less than 1% of the genes (95 out of 13,738
genes) had a number of sites greater than 500. We ran some simulation studies
similar to those presented in section 5 of the main manuscript to assess the type I
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Figure 11: Scatter plot of vˆ with respect to 2 log(BF ) based on one simulated dataset
with 10,000 genes and 20 of them associated with the case-control status. Plot a)
displays the scatter plot for BF with non-informative prior and vˆi computed using
hyperparameter αˆ (equation 23); Plots b) display scatter plot for BF with informative
prior and vˆi computed using hyperparameter αˆ (equation 23); Plot c) displays scatter
plot for BF with informative prior and vˆi computed using hyperparameter αˆ
′ (equation
30).
error under H0 assuming large genes. The simulated genes had 5000 sites and we
assumed a total sample size of 500, 1000 and 2000 individuals with the same number
of cases and controls. Each simulation run included 500 replicates. If the significance
level α = 0.05, the overall type I error rate is 0.086 for N = 500, 0.073 for N = 1000
and 0.069 for N = 2000 based on the BF with beta informative prior.
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Figure 12: QQ plot of the BF with informative prior under the null hypothesis as-
suming different sample sizes and gene sizes. The green circle symbol in each plot
represents BF with beta prior and the orange circle symbol represents BF with mix-
ture prior.
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Figure 13: Type I error rate for different methods (α = 0.05) including BF with beta
informative prior (beta inf), BF with mixture informative prior (mix inf), BF with
beta non-informative prior (beta noninf), BF with mixture non-informative prior
(mix noninf), SKAT, Burden and SKAT O.
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Figure 14: Statistical power for different methods with sample size N1 = N2 = 250
(α = 0.05) including BF with beta informative prior (beta inf), BF with mixture
informative prior (mix inf), BF with beta non-informative prior (beta noninf), BF
with mixture non-informative prior (mix noninf), SKAT, Burden and SKAT O.
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Figure 15: Statistical power for different methods with sample size N1 = N2 = 500
(α = 0.05) including BF with beta informative prior (beta inf), BF with mixture
informative prior (mix inf), BF with beta non-informative prior (beta noninf), BF
with mixture non-informative prior (mix noninf), SKAT, Burden and SKAT O.
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Figure 16: Statistical power for different methods with sample size N1 = N2 = 1000
(α = 0.05) including BF with beta informative prior (beta inf), BF with mixture
informative prior (mix inf), BF with beta non-informative prior (beta noninf), BF
with mixture non-informative prior (mix noninf), SKAT, Burden and SKAT O.
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Figure 17: Range of type I error rates over 6 complete simulation runs for the BF
with beta (BF beta) or mixture (BF mix) informative prior under different scenarios
(α = 0.05)
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Figure 18: Range of power values over 6 complete simulation runs for the BF with
beta informative prior under different scenarios (α = 0.05). Red, green and blue
bars indicate that 0%, 10% and 25% of the associated variants within the gene are
protective.
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Figure 19: Range of power values over 6 complete simulation runs for the BF with a
mixture informative prior under different scenarios (α = 0.05). Red, green and blue
bars indicate that 0%, 10% and 25% of the associated variants within the gene are
protective.
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13 Web Appendix M: Simulation Results with the
BFDR approach
We ran simulations using the sim1000G R package (Dimitromanolakis et al., 2019)
to compare the BF approach based on BFDR procedure to three competing methods
(SKAT, SKAT-O and the Burden test) based on frequentist alternative, Benjamini-
Hochberg (BH) procedure (Benjamini and Hochberg, 1995) in the context of genome-
wide inference. The datasets were simulated assuming different sample sizes N1 =
N2 = 250, N1 = N2 = 500, and N1 = N2 = 1000. For each replicate, we simulated a
total of 10,000 genes with 20 of them associated with the phenotype (case-control sta-
tus). The distribution of the number of sites over the 10,000 simulated genes mimicked
the distribution observed in the lung cancer study (Section 6 of the main manuscript)
with 46% of the genes with 20-50 sites; 36% with 50-100 sites; 17% with 100-500
sites; and 1% with 500-1000 sites. The proportion of associated variants within the
20 associated genes were decided depending on the gene sizes: 40% of associated
variants for genes with 50-100 sites, 30% for genes with 100-500 sites, and 20% for
genes with over 500 sites. In addition, we assumed that either all associated variants
were deleterious (i.e., increase risk) or there was a 5:1 ratio of deleterious/protective
RVs under each simulation scenario. In each scenario, we generated 100 replicated
genome-wide data sets. Our goal was to compare the overall empirical FDR level to
the nominal FDR level of 0.05 and also evaluate the true discovery rate (TDR), as
shown in Figures 20 and 21. The TDR is defined as the ratio of rejected true signals
over the total number of true signals.
14 Web Appendix N: Real Data Application
Quality controls
First, we filtered out sites that did not pass all filters when the VCF file was created
(not labeled as PASS under FILTER column) and also we only kept bi-allelic vari-
ants with Hardy-Weinberg tests p−value greater than 10−7, which leaves a total of
1,810,404 sites in the dataset. Second, we filtered out genotypes with low quality as
assessed by GQ score (genotype quality) less than 30 or DP (read depth) less than
10. Third, we deleted variants with missing genotype rate greater than 10 across
individuals. The MAF distribution of the remaining 1,477,890 bi-allelic variants is
displayed in Web Appendix Table 2. Fourth, we checked the gender, relatedness,
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Figure 20: Empirical FDR and TDR levels over 100 simulation replicates obtained
with the BF, Burden test, SKAT and SKAT-O for a pre-specified FDR level of
0.05 (indicated by the horizontal line). There are 20 out of 10,000 genes associ-
ated with the case-control status in each replicate and each associated gene harbours
only deleterious genetic variants (i.e., increase disease risk). BF denotes the BF with
beta informative prior using BFDR procedure. All other methods are based on the
Benjamini-Hochberg (BH) procedure.
heterozygosity rate and ethnicity of the individuals. One individual was removed
because of relatedness and gender issues, two because they were 1st degree relative of
other individuals, and one who showed extreme heterozygosity rate and was distant
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Figure 21: Empirical FDR and TDR levels over 100 simulation replicates obtained
with the BF, Burden test, SKAT and SKAT-O for a pre-specified FDR level of 0.05
(indicated by the horizontal line). There are 20 out of 10,000 genes associated with
the case-control status in each replicate and each associated gene has a 5:1 ratio of
deleterious/protective variants. BF denotes the BF with beta informative prior using
BFDR procedure. All other methods are based on the Benjamini-Hochberg (BH)
procedure.
from European ancestry based on principal component analysis. Fifth, we removed
common variants and only selected loci with MAF< 0.01 in the dataset. Since we
chose genes as the testing units, in order to conduct the testing robustly, we removed
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Table 2: MAF distribution of SNPs in the lung cancer WES study
MAF 0 (0,0.01) [0.01,0.05) [0.05,0.5) Total
#(SNPs) 785995 488182 64330 140373 1477890
Proportion (%) 53.2 33.0 4.4 9.5 100
Table 3: Number of site distribution in the lung cancer WES study.
Number of sites [20,50) [50,100) [100,500) 500+ Total
#(Genes) 7201 4364 2078 95 13738
Proportion (%) 52.4 31.8 15.1 0.7 100
genes with less than 20 loci (sites) for the association testing. For analysis of each
chromosome, we further removed individuals with missing genotype rate greater than
5. Finally, we excluded highly correlated RVs for the KS test, ie. Pearson correlation
> 0.99. Among the 13,738 genes with at least 20 sites in the clean dataset, the dis-
tribution of the number of sites within each gene is shown in Web Appendix Table
3.
Additional results
15 Web Appendix O: Estimation of parameters K∗
and K∗η∗ in the hyperprior distribution
In the Theorem 1 of the main manuscript, it is assumed thatK∗ →∞ andK∗η∗ →∞.
In this section, the distributions of log(K∗) and log(K∗η∗) for the BF with non-
informative prior from the simulated data are compared across different simulation
scenarios with different gene sizes and sample sizes.
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Figure 22: Association results for the top gene identified by the BF with informative
prior, KCNIP4 (top left side) (see Section 6) and the 5th top gene identified by
SKAT, Y AP1 (top right side) (see Table 5). The top two figures show the difference
of standardized RV counts between cases and controls, Y˜2v − Y˜1v (defined in section
3.5). The bottom two figures compare the CDF of p-values for each gene to the
empirical null distribution. The blue line represents the null distribution of p-values
based on RV tests over all genes across the genome. The red line represents the CDF
of RV p-values from the gene displayed. The one-sided KS test is detecting an excess
of small p-values in each gene (the red line is above the blue line for small p-values).
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Figure 23: Estimation of K∗ under different simulation scenarios, for BF with non-
informative prior (p = 1). The result is based on 1000 genes simulated under H0. It
shows that K∗ increases with the gene size. Based on the value of log(K∗) from the
simulated data, the assumption K∗ → ∞ seems realistic and the asymptotic results
from Theorem 1 valid.
16 Data and code
Our simulation approach and BF method are implemented respectively in the R
package sim1000G available on CRAN and rareBF available on Github
(https://github.com/adimitromanolakis/rareBF). Besides, Toronto lung cancer WES
data is available through dbGaP (https://www.ncbi.nlm.nih.gov/gap).
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Figure 24: Estimation of K∗η∗ under different simulation scenarios, for BF with non-
informative prior (p = 1). The result is based on 1000 genes simulated under H0.
Based on the value of log(K∗η∗) from the simulated data, the assumption K∗η∗ →∞
seems realistic and the asymptotic results from Theorem 1 valid. Caution is however
necessary when both sample size and number of sites are small, as shown in the upper
left panel of the figure.
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Table 5: Top 20 genes identified by SKAT, Burden and SKAT-O methods
SKAT1 SKAT BF2 Burden3 Burden BF4 SKAT-O5 SKAT-O BF6
p-value rank p-value rank p-value rank
TERT 2.63E-05 220 ERAP2 2.97E-05 18 TERT 1.55E-05 220
INPP4B 4.28E-05 2015 TET2 7.83E-05 50 PLEKHG7 1.78E-05 5
DPF2 1.88E-04 586 DOCK4 1.96E-04 29 ERAP2 9.01E-05 18
CEACAM7 2.44E-04 6809 TM4SF5 2.25E-04 36 INPP4B 1.32E-04 2015
YAP1 3.50E-04 2880 TLR6 2.28E-04 7 TET2 2.19E-04 50
NCKIPSD 3.56E-04 1024 PLA2G5 2.50E-04 992 TM4SF5 2.43E-04 36
PPP1R13L 4.70E-04 1332 ATP1A3 2.93E-04 99 PLA2G5 2.49E-04 992
MARK4 6.16E-04 10646 AKR1A1 3.16E-04 24 CEACAM7 3.65E-04 6809
PPP2R2C 6.21E-04 1644 TERT 3.49E-04 220 DOCK4 3.79E-04 29
SLC30A4 7.30E-04 381 PLEKHG7 3.80E-04 5 TLR6 4.10E-04 7
STARD3 7.55E-04 7842 PIP5K1B 4.43E-04 42 DPF2 4.58E-04 586
INPPL1 7.90E-04 1099 SNCA 4.90E-04 35 SCYL1 4.65E-04 188
ELL 8.36E-04 1522 LCMT2 5.37E-04 81 ATP1A3 4.99E-04 99
ABCD4 8.94E-04 5730 UNC45B 5.48E-04 38 REG4 5.91E-04 6
REG4 9.25E-04 6 PID1 5.61E-04 111 ABCD4 6.40E-04 5730
CD1C 9.47E-04 336 PEPD 6.98E-04 67 AKR1A1 6.58E-04 24
COMT 9.97E-04 3712 SNRPN 7.22E-04 94 YAP1 8.55E-04 2880
PIP5K1C 1.08E-03 7190 SNURF 7.60E-04 94 NCKIPSD 8.72E-04 1024
ZNF638 1.11E-03 1327 ZC3HC1 8.00E-04 148 NUBPL 8.88E-04 219
RASA1 1.13E-03 3547 OVCH2 8.00E-04 223 SNCA 9.56E-04 35
1. Top 20 genes identified by SKAT;
2. Ranking of BF with beta informative prior for the top-ranking genes identified by SKAT;
3. Top 20 genes identified by Burden;
4. Ranking of BF with beta informative prior for the top-ranking genes identified by Burden;
5. Top 20 genes identified by SKAT-O;
6. Ranking of BF with beta informative prior for the top-ranking genes identified by SKAT-O.
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Table 6: For the top 100 genes identified by the BF and other competing methods,
proportion of genes falling in each gene size category in the lung cancer WES study.
Number of sites in the gene [20,50) [50,100) [100,500) 500+
BF (beta informative prior) 53% 34% 10% 3%
BF (mixture informative prior) 42% 39% 16% 3%
BF (beta non-informative prior) 51% 39% 9% 1%
BF (mixture non-informative prior) 35% 39% 25% 1%
SKAT 40% 40% 17% 3%
Burden 51% 37% 11% 1%
SKAT-O 52% 35% 11% 2%
45
